ClinicalTrials.gg
CompletedNCT07190430Updated Sep 9, 2026

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

A Phase 1 interventional study of PF-08049820 and Midazolam in Atopic Dermatitis, sponsored by Pfizer. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
45th of 47
16 · median 121
Started
2025
with 4 others
Phase 1
13 of 58
1 open now
Registered
52nd of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 45th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2025, is one of 13 in phase 1, and was the 52nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies. The other medicines include:

  • Birth control pills (containing ethinyl estradiol and levonorgestrel)
  • Midazolam (used to help people relax or sleep)
  • Dabigatran etexilate (used to prevent blood clots)

This study is seeking participants who:

  • are female and are 18 years or older
  • weigh more than 110 pounds (50 kg)
  • have a healthy body weight (not too low or too high)
  • are generally healthy with no serious medical problems. People with serious health problems, recent medicine use, or who had certain vaccines recently cannot join.
  • are willing to follow all the study rules The study has 6 parts, and each part happens one after the other. In the first 3 parts, participants take just one dose of each medicine (midazolam, dabigatran, and birth control pills) to see how these medicines work alone. In the last 3 parts, they take PF-08049820 twice a day, along with one of the other medicines, to see how PF-08049820 changes the way those medicines move through the body. The whole study will take about 12 to13 weeks and participants will stay overnight in the clinic for about 25 days.
03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants ≥18 years of age, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • of 16 to 32 kg/m2; and a total body weight >50 kg (110 lb).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • History of infection, , or ; positive testing for HIV, Hepatitis B surface antigen (HBsAg), Antibody to hepatitis B surface antigen (HBsAb), Hepatitis B core antibody (HBcAb), or Hepatitis C Virus Antibody (HCVAb). A positive HBsAb result and a history of Hepatitis B vaccination is allowed.
  • History of thromboembolic diseases.
  • History of bleeding tendencies.
  • History of myocardial infarction, unstable angina, arterial revascularization, mechanical prosthetic heart valve, stroke, New York Association Functional Class II-IV heart failure, or .
  • Any known allergy or intolerance to midazolam or other drugs in the benzodiazepine class, and/or to dabigatran etexilate, and/or to OCs.
  • Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of certain prescription or nonprescription drugs and dietary (e.g. grapefruit) and herbal supplements within up to 14 days or 5 half-lives, whichever is longer, prior to the first dose of study intervention.
  • Recent exposure to live or attenuated vaccines within 28 days of the screening visit.
  • History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening.
  • Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Baseline Midazolam

    Participants will receive a single dose of 2 mg midazolam in the morning on Day 1

    Drug: Midazolam

  • Other
    Baseline dabigatran etexilate

    Participants will receive a single dose of 150 mg dabigatran etexilate in the morning on Day 1

    Drug: Dabigatran Etexilate

  • Other
    Baseline oral contraceptives

    Participants will receive a single dose of Portia (30 mcg of ethinyl estradiol (EE) and 150 mcg of levonorgestrel (LN)) or equivalent oral tablet in the morning on Day 1

    Drug: Portia (EE and LN) or equivalent oral tablet

  • Experimental
    Drug Drug Interaction (DDI) midazolam

    Participants will receive a single dose of 2 mg midazolam in the morning on Days 2 and 10 only with PF-08049820 Days 1 to 10

    Drug: PF-08049820 · Drug: Midazolam

  • Experimental
    DDI dabigatran etexilate

    Participants will receive a single dose of 150 mg dabigatran etexilate in the morning on Day 1 only with PF-08049820 Days 1 to 2

    Drug: PF-08049820 · Drug: Dabigatran Etexilate

  • Experimental
    DDI oral contraceptives

    Participants will receive a single dose of Portia (30 mcg of EE and 150 mcg of LN) or equivalent oral tablet in the morning on Day 1 only with PF-08049820 on Days 1 to 2

    Drug: PF-08049820 · Drug: Portia (EE and LN) or equivalent oral tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the curve (AUC) of Midazolam

    Time frame: From pre-dose up to 24 hours post dose in Periods 1 and 4

  2. PK: Plasma Maximum Concentration (Cmax) of Midazolam

    Time frame: From pre-dose up to 24 hours post dose in Periods 1 and 4

  3. PK: Area Under the curve (AUC) of dabigatran

    Time frame: From pre-dose up to 48 hours post dose in Periods 2 and 5

  4. PK: Cmax of dabigatran

    Time frame: From pre-dose up to 48 hours post dose in Periods 2 and 5

  5. PK: AUC of Ethinyl estradiol and levonorgestrel

    Time frame: From pre-dose up to 96 hours post dose in Periods 3 and 6

  6. PK: Cmax of Ethinyl estradiol and levonorgestrel

    Time frame: From pre-dose up to 96 hours post dose in Periods 3 and 6

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: First dose of study intervention until Follow Up Visit (28 to 35 days after the last dose)

  2. Number of Participants With Clinically Significant Change from Baseline in Laboratory Abnormalities

    Time frame: Baseline to Study Day 24

  3. Number of Participants With Clinically Significant Change from Baseline in Vital Signs

    Time frame: Baseline to Study Day 24

  4. Number of Participants With Clinically Significant Change from Baseline in 12-lead Electrocardiogram (ECG) Findings

    Time frame: Baseline to Study Day 24

07

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 2 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 24, 2025
StartActual
Oct 3, 2025
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190430
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Oct 3, 2025
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Sep 9, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-08049820 · Midazolam · Dabigatran

Start the discussion